Kyriazopoulou, E. Poulakou, G. Milionis, H. Metallidis, S. Adamis, G. Tsiakos, K. Fragkou, A. Rapti, A. Damoulari, C. Fantoni, M. Kalomenidis, I. Chrysos, G. Angheben, A. Kainis, I. Alexiou, Z. Castelli, F. Serino, F.S. Tsilika, M. Bakakos, P. Nicastri, E. Tzavara, V. Kostis, E. Dagna, L. Koufargyris, P. Dimakou, K. Savvanis, S. Tzatzagou, G. Chini, M. Cavalli, G. Bassetti, M. Katrini, K. Kotsis, V. Tsoukalas, G. Selmi, C. Bliziotis, I. Samarkos, M. Doumas, M. Ktena, S. Masgala, A. Papanikolaou, I. Kosmidou, M. Myrodia, D.-M. Argyraki, A. Cardellino, C.S. Koliakou, K. Katsigianni, E.-I. Rapti, V. Giannitsioti, E. Cingolani, A. Micha, S. Akinosoglou, K. Liatsis-Douvitsas, O. Symbardi, S. Gatselis, N. Mouktaroudi, M. Ippolito, G. Florou, E. Kotsaki, A. Netea, M.G. Eugen-Olsen, J. Kyprianou, M. Panagopoulos, P. Dalekos, G.N. Giamarellos-Bourboulis, E.J., Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial (Nature Medicine, (2021), 27, 10, (1752-1760), 10.1038/s41591-021-01499-z), Journal of Natural Medicines, (27), 1850, 2021, Lithuanian Nature Research Centre, 1861-0293